Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Scenario analyses on relative efficacy of diclofenac

From: Relative benefit-risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis

  Placebo Celecoxib Naproxen Etoricoxib Ibuprofen Acetaminophen
Scenario 4 (dose ranges) Diff CFB (95% CrI) Prob. DCF better Diff CFB (95% CrI) Prob. DCF better Diff CFB (95% CrI) Prob. DCF better Diff CFB (95% CrI) Prob. DCF better Diff CFB (95% CrI) Prob. DCF better Diff CFB (95% CrI) Prob. DCF better
Pain VAS 6 weeks −13.7 (−16.9; −10.5) >99% −4.9 (−8.3; 1.4) >99% −3.1 (−7.1; 0.9) 94% 1.6 (−2.5; 5.6) 23% −1.3 (−6.7; 4.1) 68% −9.5 (−14.8; −4.1) >99%
Pain VAS 12 weeks −10.1 (−13.2; −7.0) >99% −2.6 (−5.8; 0.5) 95% −0.9 (−4.2; 2.3) 70% 0.4 (−3.4; 4.0) 42% −1.6 (−5.8; 2.6) 77% −7.1 (−16.0; 1.7) 94%
Pain Likert 6 weeks −1.8 (−2.3; −1.2) >99% −0.4 (−1.0; 0.2) 90% −0.3 (−1.1; 0.5) 77% NA NA NA NA NA NA
Pain Likert 12 weeks −2.3 (−3.4; −1.2) >99% −1.2 (−2.3; 0.0) 98% −1.1 (−2.2; 0.0) 97% NA NA NA NA NA NA
PF VAS 6 weeks −10.0 (−15.8; −4.4) >99% −1.2 (−7.3; 4.6) 66% 0.8 (−5.4; 6.7) 40% 1.2 (−4.4; 6.5) 33% −1.0 (−7.6; 5.3) 63% −6.7 (−15.1; 1.2) 95%
PF VAS 12 weeks −4.5 (−11.9; 2.8) 89% 2.3 (−5.3; 10.0) 27% 5.9 (−1.9; 13.6) 7% 5.3 (−2.4; 13.0) 9% 3.1 (−5.3; 11.4) 23% −7.1 (−14.2; 0.1) 97%
PF Likert 6 weeks −6.7 (−9.1; −4.4) >99% −2.2 (−4.5; 0.2) 96% −3.2 (−6.2; −0.2) 98% NA NA NA NA NA NA
PF Likert 12 weeks −7.7 (−10.7; −4.7) >99% −3.8 (−6.9; −0.7) >99% −3.6 (−6.7; −0.5) 99% NA NA NA NA NA NA
PGA VAS 6 weeks −16.6 (−24.3; −9.0) >99% −7.1 (−15.1; 0.8) 96% −7.0 (−15.3; 1.3) 95% −4.3 (−12.4; 3.8) 85% −5.3 (−13.9; 3.3) 89% NA NA
PGA VAS 12 weeks −14.1 (−21.4; −6.8) >99% −6.6 (−14.1; 0.9) 96% −4.6 (−12.4; 3.0) 89% −2.4 (−10.0; 5.2) 74% −5.5 (−14.1; 3.1) 90% NA NA
PGA Likert 6 weeks −0.5 (−0.7; −0.3) >99% −0.2 (−0.4; −0.1) >99% −0.1 (−0.2; 0.1) 76% NA NA NA NA NA NA
PGA Likert 12 weeks NA NA NA NA NA NA NA NA NA NA NA NA
Scenario 5 (effect sizes) Diff CFB (95% CrI) Prob. DCF better Diff CFB (95% CrI) Prob. DCF better Diff CFB (95% CrI) Prob. DCF better Diff CFB (95% CrI) Prob. DCF better Diff CFB (95% CrI) Prob. DCF better Diff CFB (95% CrI) Prob. DCF better
Pain 6 weeks −0.7 (−0.9; −0.4) >99% −0.3 (−0.5; 0.0) 98% −0.2 (−0.5; 0.1) 92% 0.0 (−0.3; 0.3) 54% −0.1 (−0.4; 0.2) 75% −0.5 (−0.8; −0.1) >99%
Pain 12 weeks −0.5 (−0.7; −0.3) >99% −0.2 (−0.4; 0.0) 98% −0.2 (−0.4; 0.0) 95% −0.1 (−0.3; 0.1) 70% −0.2 (−0.4; 0.1) 94% −0.4 (−0.8; 0.1) 93%
PF 6 weeks −0.5 (−0.6; −0.3) >99% −0.1 (−0.3; 0.1) 87% 0.0 (−0.2; 0.2) 51% 0.0 (−0.2; 0.2) 51% −0.1 (−0.3; 0.1) 83% −0.3 (−0.5; 0.0) 98%
PF 12 weeks −0.4 (−0.9; 0.2) 90% −0.1 (−0.6; 0.5) 60% 0.1 (−0.5; 0.6) 42% 0.0 (−0.5; 0.6) 44% 0.0 (−0.6; 0.5) 55% −0.6 (−1.1; 0.0) 98%
PGA 6 weeks −0.8 (−0.9; −0.6) >99% −0.2 (−0.4; −0.1) >99% −0.3 (−0.5; −0.1) >99% −0.2 (−0.4; −0.1) >99% −0.4 (−0.6; −0.2) >99% NA NA
PGA 12 weeks NA NA NA NA NA NA NA NA NA NA NA NA
  1. Pain VAS, PF VAS, and PGA VAS are in mm. Pain Likert scale runs from 0 to 20, PF Likert scale runs from 0 to 68, and PGA Likert scale runs from 0 to 5. CFB, change from baseline; CrI, credible interval; VAS, visual analogue scale; PF, physical functioning; PGA, patient global assessment; DCF, diclofenac; NA, data not available.
  2. Scenario 4: combining all doses of NSAIDs and COXIBs in OA and RA into a dose range, namely: diclofenac 75 to 150 mg/day, naproxen 500 to 1,000 mg/day, ibuprofen 1,200 to 2,400 mg/day, celecoxib 100 to 400 mg/day, and etoricoxib 30 to 90 mg/day; Scenario 5: combining VAS and Likert scales using effect sizes, as described in the Methods section.